AC Immune SA Expected to Post FY2026 Earnings of ($1.08) Per Share (NASDAQ:ACIU)

AC Immune SA (NASDAQ:ACIU – Get Rating) – Equities researchers at SVB Leerink issued their FY2026 EPS estimates for shares of AC Immune in a note issued to investors on Thursday, April 28th. SVB Leerink analyst M. Goodman forecasts that the company will earn ($1.08) per share for the year.

AC Immune (NASDAQ:ACIU – Get Rating) last released its earnings results on Tuesday, March 22nd. The company reported ($0.28) earnings per share (EPS) for the quarter.

A number of other research firms have also issued reports on ACIU. HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of AC Immune in a report on Wednesday, March 23rd. Zacks Investment Research lowered shares of AC Immune from a “buy” rating to a “hold” rating in a report on Friday, March 25th. Finally, StockNews.com lowered shares of AC Immune from a “hold” rating to a “sell” rating in a report on Thursday, March 24th.

NASDAQ:ACIU opened at $3.58 on Monday. The firm has a market cap of $298.85 million, a price-to-earnings ratio of -3.38 and a beta of 0.84. The company’s 50-day moving average is $3.96 and its two-hundred day moving average is $4.81. AC Immune has a 12-month low of $3.34 and a 12-month high of $12.61.

Several hedge funds have recently made changes to their positions in the company. Advisor Group Holdings Inc. lifted its holdings in shares of AC Immune by 320.0% during the 3rd quarter. Advisor Group Holdings Inc. now owns 4,200 shares of the company’s stock worth $28,000 after acquiring an additional 3,200 shares during the period. Bank of America Corp DE lifted its holdings in shares of AC Immune by 569.9% during the 2nd quarter. Bank of America Corp DE now owns 4,247 shares of the company’s stock worth $34,000 after acquiring an additional 3,613 shares during the period. Virtus ETF Advisers LLC lifted its holdings in shares of AC Immune by 14.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 32,852 shares of the company’s stock worth $163,000 after acquiring an additional 4,158 shares during the period. Barclays PLC lifted its holdings in shares of AC Immune by 5,889.8% during the 3rd quarter. Barclays PLC now owns 7,068 shares of the company’s stock worth $48,000 after acquiring an additional 6,950 shares during the period. Finally, Two Sigma Securities LLC purchased a new position in shares of AC Immune during the 3rd quarter worth about $76,000. Institutional investors and hedge funds own 24.42% of the company’s stock.

About AC Immune (Get Rating)

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Featured Stories